Physician profile
Frank Wilklow
NPI 1407939259
$11,811.25
in general payments reported to CMS, 2019-2025
36 companies · $2,725 in 2025
The $2,725 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $764 · 2021: $1,287 · 2022: $2,664 · 2023: $1,850 · 2024: $1,715 · 2025: $2,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,439 · Travel and Lodging: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,438.88 |
| Travel and Lodging | $850.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,228.78 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Endologix LLC | $1,238.66 | 2022-2023 | Alto Abdominal Stent Graft System |
| Abiomed | $898.70 | 2019-2025 | Impella |
| Shockwave Medical, INC | $884.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $668.72 | 2019-2025 | |
| Saranas, INC. | $639.57 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $475.32 | 2023-2025 | Onpattro |
| Cardiovascular Systems INC. | $469.17 | 2020-2023 | Diamondback Coronary |
| Amgen INC. | $312.97 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $304.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $288.30 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $283.64 | 2019-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $239.36 | 2021-2025 | Watchman Flx, Avvigo Guidance System, Comet |
| Novo Nordisk INC | $223.44 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $175.42 | 2022-2024 | Xarelto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $171.84 | 2023-2025 | Synergy Ablation System |
| Regeneron Healthcare Solutions, INC. | $131.67 | 2019-2025 | Evkeeza |
| Irhythm Technologies, INC. | $112.32 | 2024 | Zio Monitor, Zio Xt Patch |
| Inari Medical, INC. | $110.89 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $98.97 | 2024-2025 | Verquvo |
| Medtronic, INC. | $93.40 | 2021-2023 | Hawkone, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.82 | 2024-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $76.73 | 2019 | |
| Recor Medical INC | $76.53 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.82 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $67.60 | 2021-2025 | Nexletol |
| Canon Medical Systems USA, INC. | $62.35 | 2023 | Toshiba Scanner |
| Bridgebio Pharma, INC. | $55.17 | 2025 | Attruby |
| Gilead Sciences, INC. | $50.06 | 2019 | |
| Angiodynamics, INC. | $47.09 | 2023 | Alphavac |
| Lilly USA, LLC | $36.62 | 2024-2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $35.61 | 2025 | |
| Baxter Healthcare | $34.54 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $21.32 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.95 | 2023 | Inpefa |
| Philips North America LLC | $20.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wilklow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.